Mersana Therapeutics, Inc. financial statements, including revenue, expenses, profit, and loss
The total revenue of MRSN for the last quarter is 10.70 M USD, and it's 39.01% higher compared to the previous quarter. The net income of Q4 23 is -19.54 M USD.